Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele W L Teng

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
Oncoimmunology|August 2, 2014
Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppressionMark J Smyth, Michele W L Teng
Cancer Discovery|August 4, 2016
Checkpoint Immunotherapy: Picking a WinnerMichele W L Teng, Rajiv Khanna, Mark J Smyth
Cold Spring Harbor Perspectives in Biology|July 19, 2017
Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in CancerJuming Yan, Mark J Smyth, Michele W L Teng
Genome Medicine|October 27, 2016
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?Jake S O'Donnell, Mark J Smyth, Michele W L Teng
Trends in Immunology|August 20, 2013
A balance of interleukin-12 and -23 in cancerShin Foong Ngiow, Michele W L Teng, Mark J Smyth
Nature Reviews. Clinical Oncology|December 8, 2018
Cancer immunoediting and resistance to T cell-based immunotherapyJake S O'Donnell, Michele W L Teng, Mark J Smyth
Cancer Research|October 20, 2011
Prospects for TIM3-Targeted Antitumor ImmunotherapyShin Foong Ngiow, Michele W L Teng, Mark J Smyth
Cancer Cell|December 17, 2011
Stable IL-10: a new therapeutic that promotes tumor immunityMichele W L Teng, Phillip K Darcy, Mark J Smyth
Nature Reviews. Cancer|October 24, 2017
Targeting immunosuppressive adenosine in cancerDipti Vijayan, Arabella Young, Michele W L Teng, et al.
Seminars in Cancer Biology|May 4, 2017
PI3K-AKT-mTOR inhibition in cancer immunotherapy, reduxJake S O'Donnell, Daniela Massi, Michele W L Teng, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Oncoimmunology|August 2, 2014
Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppressionMark J Smyth, Michele W L Teng
Cancer Discovery|August 4, 2016
Checkpoint Immunotherapy: Picking a WinnerMichele W L Teng, Rajiv Khanna, Mark J Smyth
Cold Spring Harbor Perspectives in Biology|July 19, 2017
Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in CancerJuming Yan, Mark J Smyth, Michele W L Teng
Genome Medicine|October 27, 2016
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?Jake S O'Donnell, Mark J Smyth, Michele W L Teng
Trends in Immunology|August 20, 2013
A balance of interleukin-12 and -23 in cancerShin Foong Ngiow, Michele W L Teng, Mark J Smyth
Nature Reviews. Clinical Oncology|December 8, 2018
Cancer immunoediting and resistance to T cell-based immunotherapyJake S O'Donnell, Michele W L Teng, Mark J Smyth
Cancer Research|October 20, 2011
Prospects for TIM3-Targeted Antitumor ImmunotherapyShin Foong Ngiow, Michele W L Teng, Mark J Smyth
Cancer Cell|December 17, 2011
Stable IL-10: a new therapeutic that promotes tumor immunityMichele W L Teng, Phillip K Darcy, Mark J Smyth
Nature Reviews. Cancer|October 24, 2017
Targeting immunosuppressive adenosine in cancerDipti Vijayan, Arabella Young, Michele W L Teng, et al.
Seminars in Cancer Biology|May 4, 2017
PI3K-AKT-mTOR inhibition in cancer immunotherapy, reduxJake S O'Donnell, Daniela Massi, Michele W L Teng, et al.
Pageof 9